Splice modulating oligomers as cancer therapeutics
- PMID: 36051750
- PMCID: PMC9423660
- DOI: 10.18632/genesandcancer.222
Splice modulating oligomers as cancer therapeutics
Keywords: T regulatory cells; dominant negatives; prolactin receptors; receptor isoforms; tumor microenvironment.
Conflict of interest statement
CONFLICTS OF INTEREST The University of California, Riverside holds the patent for this approach and KEC and AMW are inventors.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
